前瞻性2期试验:挽救性近距离放疗联合间质热疗再程治疗局部复发前列腺癌的长期结果
这项多中心前瞻性2期试验纳入109例既往外照射放疗后局部复发前列腺癌患者,采用超声引导挽救性近距离放疗联合间质热疗。中位随访64个月,晚期≥3级胃肠和泌尿生殖毒性是主要终点,未观察到≥2级晚期直肠毒性,3级尿失禁发生率为7.3%。5年累积局部复发率29%,5年生化无病生存率58.9%,总生存率85.5%。
要点
- 挽救性近距离放疗联合间质热疗的晚期严重毒性低,未观察到≥2级晚期直肠毒性。
- 3级尿失禁发生率为7.3%(8/109),其余晚期泌尿毒性多为1-2级。
- 5年累积局部复发率29%,5年生化无病生存率58.9%,总生存率85.5%。
核心结论
- 对既往放疗后局部复发前列腺癌,挽救性近距离放疗联合间质热疗有效且晚期毒性很低。
- 因缺乏有意义的随机对照研究,间质热疗能否进一步提高单纯挽救性近距离放疗的疗效尚不明确。
研究设计与样本
- 多中心前瞻性2期试验,2015年至2020年纳入109例既往外照射放疗后局部复发前列腺癌患者。
- 患者接受间质HDR近距离放疗30 Gy分3次(间隔21天,EQD2 α/β=3 Gy为78.0 Gy)或间质PDR近距离放疗60 Gy分2次(间隔28天,EQD2 α/β=3 Gy为71.5 Gy)。
- 所有患者采用塑料针行间质近距离放疗,每次/每程近距离放疗前1小时内或期间行间质热疗,治疗时间60分钟,目标温度至少40-41°C。
- 主要终点为晚期≥3级胃肠和泌尿生殖副作用发生率,按CTCAE 4.03评估;次要终点包括累积局部复发率、生化无病生存、总生存、无病生存和癌症特异性生存。
- 试验注册号ClinicalTrials.gov NCT03238066。
主要发现
- 中位随访64个月,既往放疗与挽救性近距离放疗的中位间隔为77个月(范围20.4-244个月)。
- 未观察到≥2级晚期直肠毒性;3级尿失禁8/109例(7.3%),1-2级尿失禁7/109例(6.4%)。
- 其他晚期泌尿生殖副作用均为1-2级:尿潴留8/109例(7.2%),尿频5/109例(4.6%),尿急2/109例(1.8%)。
- 全组5年累积局部复发率为29%,累积淋巴结复发率为6.8%。
- Kaplan-Meier估计5年生化无病生存率为58.9%,无转移生存率77.7%,癌症特异性生存率92.7%,总生存率85.5%。
关键数值与推荐
- 晚期≥3级胃肠和泌尿生殖毒性为主要终点,未报告≥3级胃肠毒性,3级尿失禁发生率为7.3%。
- 未观察到≥2级晚期直肠毒性。
- 5年累积局部复发率29%,5年累积淋巴结复发率6.8%。
- 5年生化无病生存率58.9%,无转移生存率77.7%,癌症特异性生存率92.7%,总生存率85.5%。
临床怎么用
- 对既往放疗后局部复发前列腺癌,可考虑挽救性近距离放疗联合间质热疗,晚期严重毒性低。
- 治疗选择HDR或PDR近距离放疗方案时需结合患者具体情况,本试验未比较两种方案的疗效差异。
- 间质热疗的附加获益尚不明确,临床决策时应向患者说明缺乏随机对照证据。
局限性
- 缺乏有意义的随机对照研究,无法明确间质热疗是否进一步提高单纯挽救性近距离放疗的疗效。
- 原文未报告无进展生存、生活质量等患者报告结局。
- 原文未报告间质热疗相关不良反应的单独分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: This prospective Phase 2 trial investigates efficacy and side effects of ultrasound-guided salvage brachytherapy with interstitial hyperthermia in locally recurrent prostate cancer following previous radiation therapy. MATERIALS AND METHODS: Altogether 109 patients with locally recurrent prostate cancer after previous external beam radiation therapy were enrolled in this Phase 2, multicentric prospective trial between 2015 and 2020. Patients received either 30 Gy in three fractions 21 days apart (78.0 Gy, EQD2, α/ β = 3 Gy) using interstitial HDR-brachytherapy alone or 60 Gy in 2 sessions 28 days apart (71.5 Gy (EQD2, α/β = 3 Gy) using interstitial PDR-brachytherapy alone. We performed the interstitial brachytherapy in all patients with plastic needles. Additionally, interstitial hyperthermia treatment was executed within one hour before or during every brachytherapy fraction/series for a therapeutic time of 60 min and a target temperature of 40-41 °C, at least. The primary endpoint of this prospective phase 2 trial was rate of late Grade ≥ 3 gastrointestinal (GI) and genitourinary (GU) side effects. Treatment-related toxicity was evaluated according to the Common Toxicity Criteria for Adverse Events version 4.03 (CTCAE). Secondary endpoints were cumulative local recurrence rate, biochemical disease-free survival (bDFS), overall survival (OS), disease-free survival (DFS) and cancer-specific survival. This trial is registered with ClinicalTrials.gov number NCT03238066. RESULTS: Median follow-up was 64 months. Median time between previous radiation therapy and salvage brachytherapy was 77 months (range 20.4 - 244 months). Serious late toxicity was generally low. Importantly we did not register any grade ≥ 2 of late rectal toxicities. We observed Grade 3 urinary incontinence in 8/109 patients (7.3%), with further seven patients scoring urinary incontinence Grade 1 or 2 toxicity (7/109, 6.4%). All other late urogenital side effects were only grade 1 or 2: urinary retention by 8/109 (7.2%), urinary frequency 5/109 (4.6%) and urinary urgency in 2/109 patients (1.8%). The cumulative 5 years local recurrence rate (cLRR) and cumulative lymph-node recurrence rate (cLndRR) for all patients was 29% and 6.8%, respectively. Five years-biochemical disease-free survival estimates according Kaplan-Meier were 58.9%. Five years metastases-free survival, cancer specific survival and overall survival estimates according Kaplan-Meier were 77.7%, 92.7% and 85.5%, respectively. CONCLUSIONS: Salvage brachytherapy with interstitial hyperthermia in local recurrent, previously irradiated, prostate cancer is effective with very low late toxicity. Since there are no meaningful randomized comparative studies available, it remains unclear whether the additional use of interstitial hyperthermia can further improve the effectiveness of salvage brachytherapy alone.
引用
- Strnad V, Dąbkowski M, Dąbrowski T, et al. Prospective Phase 2 Trial: Long-term results of a salvage brachytherapy combined with interstitial hyperthermia as Re-Irradiation for locally recurrent prostate Carcinoma. Radiother Oncol. 2026. PMID: 41702454. doi:10.1016/j.radonc.2026.111446
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。